Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018

Spark Therapeutics (ONCE) is a leader in the field of gene therapy. The company targets debilitating genetic diseases by developing potentially one-time, life-altering treatments. 

Spark Therapeutics’ pipeline of gene therapy product candidates targets the retina, liver, and the central nervous system.

Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations, and ten have given it “buy” recommendations. Five analysts have given the stock “hold” recommendations, while one has given it a “strong sell.” The mean rating for the stock is 2.2, and its target price is $70.05.

Of the total 22 analysts covering Pfizer (PFE) in April 2018, two have given the stock “strong buy” recommendations, and nine have given it “buys.” Nine analysts have given Pfizer “hold” recommendations, while two have given it “strong sell” recommendations. The mean rating for the stock is 2.59, and its target price is $40.11.

Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in April 2018, eight have given the stock “strong buy” recommendations, 11 have given it “buy” recommendations, and four have given it “hold” recommendations. The mean rating for the stock is 1.83, and its target price is $114.3.

Of the 12 analysts covering Achaogen (AKAO) in April 2018, five have given the stock “strong buy” recommendations, six have given it “buy” recommendations, and one analyst has given it a “sell.” The mean rating for the stock is 1.75, and its target price is $21.56.

In the next part of the series, we’ll take a look at the product pipeline of Spark Therapeutics.